No Safe Level: Study Links Even Low Alcohol Intake to Higher Cancer Risk

Seattle, Washington – Even a single daily drink could be enough to raise the risk of cancer, according to a major global study that delivers one of the strongest warnings yet about alcohol’s impact on human health. The massive analysis, covering 843 scientific studies and millions of people worldwide, found that alcohol is linked to a wide range of serious diseases, with cancer risks increasing even at low levels of drinking. Researchers declared that the findings reinforce a blunt scientific reality: alcohol is a known cause of cancer, officially classified as a Group 1 carcinogen by the World Health Organization’s International Agency for Research on Cancer (IARC) — the same category as tobacco, asbestos, and ionising radiation. And crucially, they warn there may be no completely safe level of consumption when it comes to cancer.

The study, published in Nature Health on June 1, 2026, examined alcohol’s effects on 20 major diseases, including multiple cancers, liver failure, heart disease, infections, and brain disorders. Across almost every category, the risks rose as drinking increased, but in several cancers, damage began at surprisingly low intake levels. The research applied the Institute for Health Metrics and Evaluation’s Burden of Proof (BoP) meta-analytic framework to carefully account for differences across studies and determine the most conservative estimate supported by the data.

One of the most alarming findings involved cancers of the throat and upper airways. The study found that pharyngeal cancer (excluding nasopharyngeal cancer) showed the strongest association, with at least a 105% increase in risk at average consumption levels — earning the highest five-star rating in the study’s evidence grading system. At around two alcoholic drinks per day (20g of alcohol), researchers found a 56% higher risk of certain pharyngeal cancers compared with non-drinkers. At higher levels, the danger escalated sharply, with risk more than tripling in some cases. At 40 grams per day (approximately four standard drinks), the mean relative risk reached 2.73 (230-323% increase), and at 76 grams per day (about 7.5 drinks), risk soared to 4.24 times higher than non-drinkers. The dose-response relationship for pharyngeal cancer was found to be non-linear, with risk increasing steeply at lower intake levels before levelling off at higher exposures. This means the greatest proportional increase in risk occurs at relatively low levels of drinking.

READ ALSO:

• Power Outage Hits Five States, Niger Republic as TCN Begins Transmission Line Repairs
• Toyota Motor Show Roars into Lagos Tomorrow with Test Drives, Debates, Free Diagnostics, Others
• Oyo Boils as Teachers Strike, Protesters Demand Freedom for Abducted Pupils

The study found harmful associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Even consumption below one standard drink per day (less than 10 grams of pure alcohol) was associated with elevated risk for cancers of the pharynx, colorectum, esophagus, breast, liver, pancreas, and prostate. Laryngeal cancer, colorectal cancer, and lip and oral cavity cancer showed moderate evidence of harm, with the analysis indicating risk increases of at least 22% to 49% (three-star associations). Cirrhosis and other chronic liver diseases showed at least a 40% increase in risk, while pancreatitis showed at least a 22% increase (three-star associations). Esophageal cancer, breast cancer, liver cancer, pancreatic cancer, and prostate cancer showed weaker but consistent evidence of harm, with risks rising steadily as consumption increased (two-star associations). Of all cancers studied, stomach cancer was the one health outcome needing additional evidence to better understand the strength of the relationship.

The study’s findings challenge the widespread belief that moderate drinking is harmless. While some earlier research has suggested that small amounts of alcohol might offer limited protection against conditions such as heart disease, dementia, and diabetes, the authors of the new study explained that these findings are uncertain and likely influenced by differences in lifestyle, diet, and health status between drinkers and non-drinkers. For several non-cancer outcomes, the dose-response relationship was J- or U-shaped. Type 2 diabetes showed a small reduction in risk of at least 4.5% at low-to-moderate intake levels. Alzheimer’s disease and other dementias showed a reduction of at least 6.4% at low-to-moderate intake levels. For ischaemic heart disease, ischaemic stroke, and haemorrhagic stroke, evidence of lower risk at low-to-moderate intake was inconsistent. However, importantly, any possible protective effects disappeared as alcohol intake increased, while cancer risks continued to rise. At higher levels of consumption, the evidence points to increased risk across every outcome examined. Atrial fibrillation and flutter showed increased risk, with the analysis indicating at least a 6% increase.

The mechanisms through which alcohol increases cancer risk are well-established. According to health authorities, ethanol and its main metabolite acetaldehyde can damage DNA in cells, leading to mutations that can trigger cancer development. Alcohol also increases oestrogen levels, which is particularly important for breast carcinogenesis. It can act as a solvent for tobacco carcinogens, enhancing their cancer-causing effects, and produce reactive oxygen species and nitrogen species that can damage cellular components. Additionally, alcohol can alter folate metabolism, affecting DNA synthesis and repair. Crucially, alcohol’s carcinogenic effect is independent of the type of alcoholic beverage. The risk is the same whether the drink is beer, wine, or spirits. It is the ethanol itself — and its metabolite acetaldehyde — that causes the damage.

The researchers warned of a major public awareness gap. While most people understand the link between smoking and cancer, far fewer realise that alcohol is also a direct carcinogen. “This is not just a lifestyle issue; it is a cancer risk issue,” the study implies through its findings, highlighting alcohol as one of the most widespread avoidable causes of disease globally. According to a February 2026 survey by the Annenberg Public Policy Center, only 53% of American adults say that regularly consuming alcohol increases cancer risk — statistically unchanged from the previous year. More than a quarter (29%) remain unsure how alcohol consumption affects cancer risk. The survey noted that public awareness had improved following the U.S. Surgeon General’s January 2025 advisory on alcohol and cancer risk, which called for updated warning labels on alcoholic beverage containers. However, when the U.S. Department of Agriculture later removed the warning linking alcohol consumption to cancer from the Dietary Guidelines, it “turned its back on a substantial body of research,” according to APPC Director Kathleen Hall Jamieson.

READ ALSO:

• ‘No Evidence’: Atiku Camp Fires Back at Babachir Lawal Over ADC Rigging Claims
• Police Warn Nigerians Against Reprisal Over Fresh South Africa Xenophobic Attacks
• Breaking: CBN Redeploys All Four Deputy Governors in Major Leadership Shake-Up

Alcohol consumption accounts for an estimated 741,300 new cases of cancer worldwide annually (about 4% of all new cancer cases) and contributes to nearly 400,000 deaths due to cancer every year. Half of all alcohol-attributable cancers in the WHO European Region are caused by “light” and “moderate” alcohol consumption — defined as less than 1.5 litres of wine, less than 3.5 litres of beer, or less than 450 millilitres of spirits per week. The World Health Organization’s Regional Office for Europe and IARC launched a new volume of the IARC Handbooks of Cancer Prevention in October 2025, focusing specifically on the impact on cancer of reduction or cessation of alcohol consumption and the effectiveness of alcohol policies.

The authors called for stronger public warnings, clearer labelling, and updated health guidance that reflects alcohol’s cancer risk more directly. The UK Government’s National Cancer Plan for England, published in February 2026, acknowledges this need, committing to mandatory requirements for alcoholic drinks to display consistent nutritional information and health warning messages. Dr. Emmanuela Gakidou, senior author and Professor at IHME, explained the complexity: “The science on alcohol and health is genuinely complex. For cancer, the evidence is consistent and unambiguous: risk rises with any level of alcohol intake. For some cardiometabolic and dementia outcomes, studies suggest small reduced risks at low-to-moderate consumption, but those associations became weaker and reversed at higher levels of drinking. Rather than interpreting these results as an endorsement of drinking, they lay out a complex map of where the evidence is strong, weak, or mixed.” Dr. Xiaochen Dai, lead author and research collaborator at IHME, added: “Our framework takes a cautious approach by accounting for differences across studies and reporting the smallest plausible effect supported by the data. For some cardiometabolic and dementia outcomes, the relationship is more complex, and the evidence is weaker, which is exactly what our star ratings are designed to make clear.”

For millions of people who see alcohol as a normal part of daily life, the message from this landmark study is stark: even “moderate” drinking may come with a hidden cost — and that cost could be cancer. The study’s findings suggest that drinking guidelines should be informed by up-to-date evidence across the full range of health outcomes, discourage heavy episodic drinking, and clearly communicate that even low-to-moderate intake is associated with elevated risk for several conditions, especially cancers. The researchers note that complete cessation of alcohol consumption is the only certain way to eliminate alcohol-related cancer risk entirely.

For quick reference, the cancer risk findings at average consumption levels are as follows: pharyngeal cancer shows at least a 105% increase with five-star evidence; laryngeal cancer shows at least a 49% increase with three-star evidence; cirrhosis and chronic liver disease show at least a 40% increase with three-star evidence; colorectal cancer shows at least a 22% increase with three-star evidence; lip and oral cavity cancer shows at least a 22% increase with three-star evidence; pancreatitis shows at least a 22% increase with three-star evidence; and esophageal, breast, liver, pancreatic, and prostate cancers show consistent evidence of harm with two-star evidence ratings.

No Safe Level: Study Links Even Low Alcohol Intake to Higher Cancer Risk

Ebola: FG Rolls Out New Airport Screening Measures, Places 10 States on High Alert

The Federal Government has stepped up surveillance at airports and other entry points across the country following the resurgence of Ebola virus disease in Uganda and the Democratic Republic of the Congo. As part of efforts to prevent the disease from entering Nigeria, authorities have introduced mandatory health screening for incoming passengers, including thousands of pilgrims expected to return from the 2026 Hajj exercise in Saudi Arabia. The measures include the deployment of a dedicated Ebola screening platform for travellers heading to Nigeria, enhanced monitoring at international airports and closer coordination among health and aviation agencies. The latest response follows the declaration by the World Health Organisation on May 17, 2026, that the outbreak linked to the Bundibugyo strain of the virus constitutes a Public Health Emergency of International Concern (PHEIC) .

Speaking on the development, the Director of Operations, Licensing and Training Standards at the Nigeria Civil Aviation Authority (NCAA) , Don Spiff, said travellers bound for Nigeria would be required to complete a health questionnaire before departure. “All passengers flying to Nigeria will have to fill out the Ebola questionnaire before they board the flight,” he said. Spiff explained that the process was being coordinated by the Nigeria Centre for Disease Control and Prevention (NCDC) alongside relevant aviation and health authorities. He noted that the precautionary measure had become even more important as the first batch of Nigerian pilgrims is expected back from Saudi Arabia from June 4 through designated international airports in Lagos, Abuja, Port Harcourt, Enugu and Kano. According to him, support would be provided for pilgrims who may experience difficulties completing the online form due to literacy challenges. He said tour operators, NCDC officials and medical personnel of the Federal Airports Authority of Nigeria (FAAN) would assist affected passengers.

Spiff disclosed that additional screening measures had been introduced for Ugandan Airlines, which operates three flights weekly into Lagos. He stated that flights arriving on Sundays and Mondays would be routed through the Hajj terminal of the Murtala Muhammed International Airport for enhanced health checks and clearance procedures. The NCAA official further revealed that directives had been issued to major international carriers, including Ethiopian Airlines, while staggered arrival schedules were being considered to ease pressure on screening facilities. He added that government agencies would assess the effectiveness of the current measures before deciding on additional interventions.

READ ALSO:

• Gunmen Kill Eight, Burn Six Houses in Imo Community Attack
• Nigeria Beat Jamaica To Clinch Fourth Unity Cup Crown In London
• Trump Will Only Accept Iran Deal That ‘Satisfies His Red Lines’

The NCAA has also instructed all international airlines operating into Nigeria to ensure passengers complete the NCDC Health Declaration Form through the designated portal before arrival. In an advisory dated May 30, 2026, the regulator said surveillance and preparedness activities had been intensified to guard against the importation of Ebola into Nigeria. “The Nigeria Civil Aviation Authority has intensified its surveillance and preparedness measures to prevent the potential importation and spread of the disease into Nigeria,” the advisory stated. The authority said it was working with the Federal Ministry of Health, the NCDC, Port Health Services, state ministries of health and international health organisations to strengthen national preparedness. Airlines were also directed to notify passengers about the health declaration requirement and provide assistance where necessary. Pilots have been instructed to immediately notify Air Traffic Control of any suspected communicable disease case onboard aircraft, while flight crew members must complete Aircraft General Declaration forms for suspected cases. Passengers unable to complete the online process before arrival would be allowed to fill paper forms at the airport, the advisory added. The latest outbreak has rekindled memories of the 2014 Ebola crisis in Nigeria, which was eventually contained after the virus was introduced into the country by Liberian-American diplomat Patrick Sawyer.

Investigations showed that health screening procedures have already commenced at the Murtala Muhammed International Airport in Lagos. Officials were seen conducting temperature checks, verifying vaccination records and gathering passenger information to support contact-tracing efforts. Similar measures have reportedly been implemented at other international airports nationwide. A security official at the Port Harcourt International Airport, who requested anonymity because he was not authorised to speak publicly on the matter, said monitoring activities by Port Health Services had been strengthened. A traveller arriving from the United Kingdom, identified simply as Adela, observed that screening procedures appeared more stringent than usual, especially for passengers arriving from African countries. The Managing Director of the Federal Airports Authority of Nigeria (FAAN) , Olubunmi Kuku, confirmed that airports across the country had been placed on high alert. “At present, there has been no reported case linked to Ebola at Nigerian airports. However, surveillance and monitoring have been significantly intensified,” she said. FAAN had earlier announced that enhanced Ebola response protocols had been activated at all international airports nationwide, with passengers from high-risk regions undergoing enhanced screening. The authority stated that any suspected case will be promptly isolated and subjected to secondary health checks in line with established national and international health protocols.

READ ALSO:

• ‘I Didn’t Buy ADC Form to Be VP,’ Amaechi Dismisses Speculation
• Appeal Court Sacks Pro-Wike’s Rivers APC Exco, Upholds Nullification of Congresses
• BREAKING: Dangote Refinery Announces New Petrol, Diesel Prices

The NCDC has activated nationwide preparedness measures and called on healthcare workers and institutions to maintain a high level of vigilance. In a significant development, the agency has placed Lagos, the Federal Capital Territory (FCT), Kano, Rivers, Enugu, Borno, Akwa Ibom, Cross River, Taraba and Adamawa on high alert over the possible importation of the deadly virus. The NCDC disclosed that a joint Dynamic Risk Assessment conducted with partners showed that “the overall risk of importation of the disease into Nigeria has been assessed as HIGH due to increasing ongoing regional transmission, international travel, regional population movement, major airports, seaports, porous land borders, informal crossings and trade routes.” The agency revealed that more than 1,000 suspected cases and 247 deaths linked to the outbreak have already been recorded in Congo and Uganda, with a fatality rate estimated at 24.6 percent. Its Director-General, Jide Idris, warned that Nigeria remains vulnerable because of international travel and the similarity between Ebola symptoms and those of diseases such as malaria and Lassa fever. He emphasised the importance of promptly identifying suspected cases and adhering strictly to infection prevention and control measures. The NCDC also clarified that the Bundibugyo Ebola strain currently has no approved vaccine or targeted treatment, making early detection and strict public health measures critical to preventing an outbreak. Existing Ebola vaccines and monoclonal antibody therapies are mainly designed for the Zaire strain and may not provide protection against the current outbreak.

A public health physician and epidemiologist, Prof Tanimola Akande, urged Nigerians to remain vigilant and support efforts aimed at preventing a possible outbreak. He warned that the disease could spread from infected animals to humans and subsequently from person to person. “Citizens can take preventive measures such as proper handling of animals during hunting and while displaying dead animals for sale. Nigerians need to be aware of Ebola and know the common symptoms so they can promptly identify suspected cases,” Akande said. He advised that suspected cases should be taken to health facilities immediately and urged Nigerians to avoid close contact with individuals showing symptoms of the disease. The epidemiologist also called for intensified surveillance at airports, seaports and land borders. “Passengers should be screened to ensure that suspected cases are identified early, isolated and moved to appropriate health facilities,” he said. Akande noted that the NCDC was already collaborating with relevant stakeholders to strengthen preparedness. He warned that the Bundibugyo strain currently responsible for the outbreak has a fatality rate of between 30 and 50 per cent and could remain undetected for weeks. “It is, therefore, very important that precautionary measures are taken by the government, partners and Nigerians to ensure that no outbreak is recorded in Nigeria,” the epidemiologist added.

As of the time of this report, Nigeria has not recorded any confirmed case of Ebola Virus Disease. The NCDC continues to monitor the situation closely and has assured citizens that all necessary protocols are in place to prevent the importation and spread of the virus. The agency urged Nigerians to remain calm but vigilant, report any suspected cases to the nearest health facility, and adhere to all public health advisories.

Ebola: FG Rolls Out New Airport Screening Measures, Places 10 States on High Alert

WHO Steps Up Ebola Response, Prioritises Vaccine Testing Amid Outbreak

The World Health Organisation (WHO) has intensified global efforts to contain the ongoing outbreak of Ebola disease caused by the Bundibugyo virus, convening top scientific and advisory groups to urgently evaluate experimental vaccines and therapeutics as cases continue to emerge in the Democratic Republic of the Congo (DRC), with additional cross-border infections reported in Uganda.

The latest outbreak has raised fresh concerns among international health authorities because the Bundibugyo ebolavirus is one of the less common species of Ebola virus, and currently has no licensed vaccine or approved therapeutic treatment, unlike the more common Zaire ebolavirus for which approved countermeasures exist.

In a statement released after a high-level emergency consultation, WHO said its expert advisory groups concluded that all promising medical countermeasures for Bundibugyo virus disease (BVD) should only be deployed within carefully designed clinical trials to ensure scientific evidence generation while maintaining strict safety and ethical standards. (who.int)

The organisation disclosed that the review involved its R&D Blueprint Technical Advisory Group, the Strategic Advisory Group of Experts on Immunisation (SAGE), and WHO’s Ebola Vaccine Working Group, which assessed all available vaccine and treatment candidates for immediate deployment feasibility.

WHO said the current outbreak underscores a major research gap in global preparedness for non-Zaire Ebola strains, particularly the Bundibugyo species, which caused significant outbreaks in Uganda in 2007 and the DRC in 2012, with fatality rates ranging between 25 and 50 per cent, according to historical outbreak data. (cdc.gov)

READ ALSO:

• Power Generation Drops by 20% as Nigerians Face Fresh Electricity Supply Woes
• Official, Black Market Dollar Rates Narrow as Naira Holds Ground
• Tinubu Deepfake: Presidency Alleges Coordinated Plot to Divide Nigerians

For treatment of confirmed infections, independent experts prioritised three investigational therapeutics for immediate clinical trial evaluation.

These include the monoclonal antibody MBP134, Maftivimab®, and the antiviral drug remdesivir, all of which have shown potential antiviral activity against filoviruses in preclinical and limited clinical settings.

The advisory groups also endorsed testing combination therapy involving a monoclonal antibody and remdesivir to determine whether combined treatment could improve survival outcomes.

WHO stressed that none of these interventions should be administered outside structured clinical protocols.

For post-exposure prophylaxis among individuals who have had direct contact with confirmed or probable cases, experts identified the oral antiviral obeldesivir as a priority candidate.

The strategy involves rapidly administering oral tablets to exposed contacts to assess whether infection can be prevented before symptom onset.

However, WHO warned that this approach depends heavily on rapid case detection and effective contact tracing, both of which remain operational challenges in some affected communities due to security concerns and difficult terrain.

On vaccines, WHO identified the single-dose rVSV Bundibugyo vaccine, developed by the International AIDS Vaccine Initiative (IAVI), as the most promising candidate for future trial deployment.

The vaccine is estimated to require seven to nine months before becoming trial-ready.

A second candidate, ChAdOx1 Bundibugyo, developed by the University of Oxford in collaboration with the Serum Institute of India, could be available for efficacy trials within two to three months, pending additional animal safety and immunogenicity data.

Experts said a single-dose vaccination strategy could be suitable for immediate ring vaccination of contacts of infected persons, while a two-dose regimen may be more appropriate for frontline health workers and other high-risk responders.

The panels also reviewed Ervebo, currently the world’s only licensed Ebola vaccine.

Although Ervebo has proven highly effective against Zaire ebolavirus, WHO said there is currently no conclusive evidence that it offers protection against the Bundibugyo strain.

As a result, the organisation advised that Ervebo should not be used outside rigorously controlled research settings specifically designed to evaluate possible cross-protection.

WHO said it is collaborating closely with the governments of the DRC and Uganda, the Africa Centres for Disease Control and Prevention (Africa CDC), the French National Agency for Research on AIDS and Viral Hepatitis (ANRS), and other global partners to fast-track ethical clinical trial protocols.

The organisation emphasised that all research activities must meet the highest international ethical standards, with affected communities actively involved in decision-making and national authorities maintaining oversight.

WHO also called for accelerated deployment of essential laboratory supplies, stronger surveillance systems, enhanced community engagement, and coordinated international funding to support rapid evaluation of Bundibugyo-specific countermeasures.

Despite the accelerated research push, WHO reiterated that the immediate priority remains containing transmission through established Ebola control measures, including rapid diagnosis, case isolation, contact tracing, infection prevention and control, community education, safe burials, and intensive surveillance.

Health officials warned that while scientific progress offers hope, effective outbreak containment will depend primarily on swift public health action and strong regional cooperation.

WHO Steps Up Ebola Response, Prioritises Vaccine Testing Amid Outbreak